VIR BIOTECHNOLOGY, INC. (VIR) News

VIR BIOTECHNOLOGY, INC. (VIR): $26.26

1.80 (+7.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VIR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 397

in industry

Filter VIR News Items

VIR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VIR News Highlights

  • For VIR, its 30 day story count is now at 29.
  • Over the past 29 days, the trend for VIR's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about VIR are GSK, BA and BEAT.

Latest VIR News From Around the Web

Below are the latest news stories about Vir Biotechnology Inc that investors may wish to consider to help them evaluate VIR as an investment opportunity.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial and clinical value drivers expected across the portfolio in 2022 – SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Yahoo | February 24, 2022

Avid (CDMO) to Report Q3 Earnings: What's in the Cards?

Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

Yahoo | February 21, 2022

Industry Analysts Just Upgraded Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Forecasts By 17%

Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | February 21, 2022

Vir Biotechnology, Inc. (VIR) Reports Next Week: Wall Street Expects Earnings Growth

Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Yahoo | February 14, 2022

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Yahoo | February 14, 2022

Vir Biotechnology: Some Option Strategies For July

No summary available.

Seeking Alpha | February 12, 2022

GSK-Vir therapy has neutralising activity against Omicron sub-variant, data shows

LONDON: An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing data from lab work. The US company said it expected to release preprint data in the coming week, with live virus data to follow. Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest. The monoclonal antibody therapy, sotrovimab, is authorised for emergency use in the United States. GSK''s COVID-related sales close to $2bn, profit boost to wane in 2022 The companies are sharing the latest data with gl...

Business Recorder | February 10, 2022

GSK-Vir therapy retains neutralising activity against Omicron sub-variant, data shows

An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing pre-clinical data.

Reuters | February 10, 2022

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.

GlobeNewswire | February 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9264 seconds.